Business Context and Reporting Period
This Form 8-K is a current report filed by Capricor Therapeutics, Inc. on June 12, 2023. The filing reports a corporate governance event: the approval and subsequent filing of an amendment to the Company's Certificate of Incorporation.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly a legal notice regarding corporate bylaws.
Material Changes
The material change reported is an amendment to the Company's Certificate of Incorporation approved by stockholders on June 12, 2023, and filed with the Delaware Secretary of State on June 13, 2023. The amendment extends exculpation provisions to limit the liability of the Company's officers for monetary damages for breach of fiduciary duty, in addition to the existing protections for directors. This change aligns the Company's charter with new Delaware General Corporation Law (DGCL) legislation effective August 1, 2022.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or management commentary regarding business performance. The primary risk context is legal: the amendment limits officer liability to the fullest extent permitted by the DGCL, with any future changes to the DGCL automatically applying to the Company's charter.
Key Facts for Investor Verification
- The amendment specifically adds liability protection for officers, which was previously not included in the Certificate of Incorporation.
- The amendment became effective on June 13, 2023.
- The change is prospective only and does not affect existing rights or protections of directors or officers at the time of the amendment.
- Investors should review Exhibit 3.1 (Certificate of Amendment) for the complete legal text of the amendment.